HK1199838A1 - Macrocyclic lrrk2 kinase inhibitors lrrk2 - Google Patents

Macrocyclic lrrk2 kinase inhibitors lrrk2

Info

Publication number
HK1199838A1
HK1199838A1 HK15100389.2A HK15100389A HK1199838A1 HK 1199838 A1 HK1199838 A1 HK 1199838A1 HK 15100389 A HK15100389 A HK 15100389A HK 1199838 A1 HK1199838 A1 HK 1199838A1
Authority
HK
Hong Kong
Prior art keywords
lrrk2
macrocyclic
kinase inhibitors
lrrk2 kinase
inhibitors
Prior art date
Application number
HK15100389.2A
Other languages
English (en)
Chinese (zh)
Inventor
Jan Hoflack
Petra Blom
Original Assignee
Ipsen Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma Sas filed Critical Ipsen Pharma Sas
Publication of HK1199838A1 publication Critical patent/HK1199838A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems
HK15100389.2A 2011-09-30 2015-01-14 Macrocyclic lrrk2 kinase inhibitors lrrk2 HK1199838A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2011067086 2011-09-30
PCT/IB2012/002318 WO2013046029A1 (fr) 2011-09-30 2012-09-28 Inhibiteurs macrocycliques de la kinase lrrk2

Publications (1)

Publication Number Publication Date
HK1199838A1 true HK1199838A1 (en) 2015-07-24

Family

ID=47326223

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15100389.2A HK1199838A1 (en) 2011-09-30 2015-01-14 Macrocyclic lrrk2 kinase inhibitors lrrk2

Country Status (18)

Country Link
US (2) US9096609B2 (fr)
EP (1) EP2760453B1 (fr)
JP (1) JP6082397B2 (fr)
KR (1) KR20140095477A (fr)
CN (1) CN104023728B (fr)
AU (1) AU2012314035B2 (fr)
BR (1) BR112014007654A8 (fr)
CA (1) CA2850350A1 (fr)
DK (1) DK2760453T3 (fr)
ES (1) ES2583477T3 (fr)
HK (1) HK1199838A1 (fr)
HU (1) HUE029728T2 (fr)
MX (1) MX342177B (fr)
PL (1) PL2760453T3 (fr)
PT (1) PT2760453T (fr)
RU (1) RU2622104C2 (fr)
UA (1) UA113186C2 (fr)
WO (1) WO2013046029A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2849999A1 (fr) * 2011-09-30 2013-04-04 Oncodesign S.A. Inhibiteurs de kinase flt3 macrocycliques
MD20140130A2 (ro) 2012-06-29 2015-04-30 Pfizer Inc. 4-(amino-substituite)-7H-pirolo[2,3-d]pirimidine noi ca inhibitori de LRRK2
EP2970333B1 (fr) * 2013-03-15 2017-05-03 Ipsen Pharma S.A.S. Inhibiteurs macrocycliques de la kinase lrrk2
US20160024114A1 (en) * 2013-03-15 2016-01-28 Oncodesign S.A. Macrocyclic rip2 kinase inhibitors
CA2906262A1 (fr) 2013-03-15 2014-09-18 Oncodesign S.A. Inhibiteurs macrocycliques de la kinase inductible par un sel
EP2994471B1 (fr) * 2013-05-06 2017-05-17 Merck Patent GmbH Macrocycles utilisés en tant qu'inhibiteurs de kinases
CA2933767C (fr) 2013-12-17 2018-11-06 Pfizer Inc. Nouvelles 1h-pyrrolo[2,3- b]pyridines 3,4-disubstituees et 7h-pyrrolo[2,3-c]pyridazines 4,5-disubstituees en tant qu'inhibiteurs de la lrrk2
WO2015136073A1 (fr) * 2014-03-14 2015-09-17 Oncodesign Sa Inhibiteurs macrocycliques de la kinase tgf-br2
EP3166637B1 (fr) 2014-07-10 2020-01-29 The J. David Gladstone Institutes Compositions et méthodes pour le traitement d'une infection par le virus de la dengue
BR112017004035B1 (pt) 2014-09-17 2023-11-14 Oncodesign Precision Medicine (OPM) Inibidores macrocíclicos de rip2 quinase e composições farmacêuticas
ES2717510T3 (es) * 2014-09-17 2019-06-21 Oncodesign Sa Inhibidores macrocíclicos de cinasa LRRK2
WO2016146651A1 (fr) 2015-03-16 2016-09-22 Oncodesign Sa Inhibiteurs macrocycliques de récepteur kinase de type activine
AU2016322813B2 (en) 2015-09-14 2021-04-01 Pfizer Inc. Novel imidazo (4,5-c) quinoline and imidazo (4,5-c)(1,5) naphthyridine derivatives as LRRK2 inhibitors
AU2017302019A1 (en) * 2016-07-28 2019-02-07 Turning Point Therapeutics, Inc. Macrocycle kinase inhibitors
KR101923852B1 (ko) * 2017-02-24 2018-11-29 재단법인 대구경북첨단의료산업진흥재단 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물
CN110891954A (zh) * 2017-07-14 2020-03-17 葛兰素史密斯克莱知识产权发展有限公司 富含亮氨酸的重复激酶2的抑制剂
CN110627812B (zh) 2018-06-25 2022-10-11 北京诺诚健华医药科技有限公司 作为trk抑制剂的杂环化合物
EP3870579A4 (fr) 2018-10-22 2022-10-19 Alumis Inc. Inhibiteurs de tyk2 et leurs utilisations
US20230357269A1 (en) * 2020-05-06 2023-11-09 Les Laboratoires Servier New macrocyclic lrrk2 kinase inhibitors
JP2024512449A (ja) * 2021-03-18 2024-03-19 レ ラボラトワール セルヴィエ 大環状ｌｒｒｋ２キナーゼ阻害剤
WO2023076404A1 (fr) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Méthodes de traitement de lupus érythémateux disséminé
US11780851B2 (en) 2021-10-27 2023-10-10 H. Lundbeck A/S LRRK2 inhibitors
CN117425660A (zh) * 2022-05-18 2024-01-19 上海翊石医药科技有限公司 一种芳杂环类化合物及其中间体、药物组合物和用途
WO2023224894A1 (fr) * 2022-05-20 2023-11-23 Merck Sharp & Dohme Llc Macrocycles servant d'inhibiteurs de lrrk2, compositions pharmaceutiques et leurs utilisations

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
BR9407686A (pt) 1993-10-01 1997-02-04 Astra Ab Processo e aparelho para o tratamento de um medicamento em pó finamente dividido uso do aparelho e aglomerados
EP0729758A3 (fr) 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines et pyrrolopyrimidines pour traiter les troubles neuronaux et autres maladies
US6043358A (en) 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
ES2294800T3 (es) 1996-07-24 2008-04-01 Bristol-Myers Squibb Pharma Company Azolo triazinas y pirimidinas.
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6194410B1 (en) 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
ATE526330T1 (de) 2000-12-28 2011-10-15 Ono Pharmaceutical Co Heterotrizyklische verbindungen als antagonisten des crf-rezeptors
DE10239042A1 (de) * 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
EA013904B1 (ru) * 2003-12-18 2010-08-30 Янссен Фармацевтика Н.В. Пиридо- и пиримидопиримидиновые производные в качестве антипролиферативных агентов
WO2006045392A2 (fr) 2004-10-21 2006-05-04 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Gene kaspp (lrrke), production de ce gene et utilisation de ce gene pour la detection et le traitement de troubles neurodegeneratifs
NO323175B1 (no) 2004-12-23 2007-01-15 Jan O Aasly Framgangsmate for a pavise en mutasjon som forarsaker arvelig parkinsonisme
FI123725B (fi) 2005-08-01 2013-10-15 Reijo Viljanen Menetelmä sahalaitteen terän jännittämiseksi ja ohjaamiseksi sekä ohjaus- ja jännityslaitteet
DE102005042742A1 (de) * 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
US7750000B2 (en) * 2005-09-02 2010-07-06 Bayer Schering Pharma Ag Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments
KR101576159B1 (ko) * 2005-11-16 2015-12-09 에스*바이오 피티이 리미티드 헤테로알킬이 결합된 피리미딘 유도체
NZ576234A (en) * 2006-11-06 2011-06-30 Supergen Inc Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
WO2008060248A1 (fr) * 2006-11-15 2008-05-22 S*Bio Pte Ltd. Pyrimidines substituées par indole, et leur utilisation dans le traitement d'un cancer
WO2008075103A1 (fr) * 2006-12-20 2008-06-26 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Indoles antiviraux
US7732434B2 (en) * 2007-04-20 2010-06-08 Bristol-Myers Squibb Company Macrocyclic acyl guanidines as beta-secretase inhibitors
JP5536647B2 (ja) * 2007-07-27 2014-07-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ピロロピリミジン
DK2283024T3 (da) * 2008-03-10 2013-08-05 Janssen Pharmaceutica Nv 4-aryl-2-anilinpyrimidiner som PLK-kinaseinhibitorer
DE102008019146A1 (de) 2008-04-16 2009-11-05 Airbus Deutschland Gmbh Enteisungssystem für ein Flugzeug
CN102428084B (zh) * 2009-03-19 2016-05-18 医疗技术研究局 化合物
CA2771176A1 (fr) * 2009-09-21 2011-03-24 F. Hoffmann-La Roche Ag Inhibiteurs macrocycliques de jak
EA021437B1 (ru) 2009-09-29 2015-06-30 Глэксо Груп Лимитед Соединения, ингибирующие lrrk2 киназную активность
EP2710018B8 (fr) * 2011-05-19 2022-02-23 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Composés macrocycliques en tant qu'inhibiteurs des protein kinases
WO2013001310A1 (fr) * 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Composés macrocycliques et leur utilisation en tant qu'inhibiteurs de cdk8
CA2849999A1 (fr) * 2011-09-30 2013-04-04 Oncodesign S.A. Inhibiteurs de kinase flt3 macrocycliques

Also Published As

Publication number Publication date
JP2014528405A (ja) 2014-10-27
MX342177B (es) 2016-09-20
PL2760453T3 (pl) 2016-11-30
AU2012314035B2 (en) 2016-12-15
CN104023728A (zh) 2014-09-03
PT2760453T (pt) 2016-08-02
RU2014117515A (ru) 2015-11-10
WO2013046029A1 (fr) 2013-04-04
US9096609B2 (en) 2015-08-04
CN104023728B (zh) 2016-11-02
AU2012314035A1 (en) 2014-05-15
RU2622104C2 (ru) 2017-06-13
BR112014007654A8 (pt) 2018-06-12
ES2583477T3 (es) 2016-09-21
HUE029728T2 (en) 2017-03-28
EP2760453A1 (fr) 2014-08-06
CA2850350A1 (fr) 2013-04-04
EP2760453B1 (fr) 2016-05-25
US20150290198A1 (en) 2015-10-15
KR20140095477A (ko) 2014-08-01
UA113186C2 (xx) 2016-12-26
JP6082397B2 (ja) 2017-02-15
MX2014003557A (es) 2014-11-26
BR112014007654A2 (pt) 2018-04-17
US20140206683A1 (en) 2014-07-24
US9370520B2 (en) 2016-06-21
DK2760453T3 (en) 2016-08-15

Similar Documents

Publication Publication Date Title
HK1199838A1 (en) Macrocyclic lrrk2 kinase inhibitors lrrk2
HK1200828A1 (en) Kinase inhibitors
HK1198764A1 (zh) 大環 激酶抑制劑
EP2710007A4 (fr) Inhibiteurs de kinase
IL228103A0 (en) Amino-quinolines as kinase inhibitors
EP2782580A4 (fr) Inhibiteurs sélectifs de kinases
IL229028A0 (en) Kinase inhibitors
GB201009731D0 (en) Kinase inhibitors
HK1199873A1 (en) Kinase inhibitors
IL232234A0 (en) Inhibitors of aminopyrimidine kinase
IL228928A0 (en) Aminopyrimidine kinase inhibitors
EP2685992A4 (fr) Amino-quinoléines en tant qu'inhibiteurs de kinase
AP2013007215A0 (en) Imidazopyridazines as AKT kinase inhibitors
HK1201460A1 (en) Pyrazine kinase inhibitors
HK1219481A1 (zh) 大環的 激酶抑制劑
PL2646448T3 (pl) Makrocykliczne inhibitory kinazy
PL2760867T3 (pl) Makrocykliczne inhibitory kinaz FLT3

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200930